Selank vs Semax: Research Comparison

What each compound is

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide built around a short fragment of the human immunoglobulin G heavy chain, the tetrapeptide tuftsin (Thr-Lys-Pro-Arg), which researchers extended at the C-terminus with Pro-Gly-Pro to improve reported metabolic stability. Semax is a separate heptapeptide whose N-terminus contains a fragment of adrenocorticotropic hormone, ACTH(4-7) (Met-Glu-His-Phe), coinciding with a corresponding site of alpha-MSH, and is likewise stabilized at the C-terminus by the biogenic tripeptide Pro-Gly-Pro. Both were developed in the same family of Russian regulatory-peptide research and share the Pro-Gly-Pro stabilizing motif, but their parent sequences (immunoglobulin-derived versus ACTH-derived) are distinct. Both are described in the literature as research compounds that, to investigators' knowledge, have not completed clinical trials.

How their studied mechanisms differ

The mechanisms reported for the two peptides diverge along their parent-sequence lines. Selank is most often studied in the context of GABAergic and anxiolytic-type signaling: in-vitro work in IMR-32 cells examined how Selank affects the expression of genes involved in GABAergic neurotransmission, and other preclinical reports describe interactions implicating the opioid system in its observed behavioral profile in rodents. Semax, by contrast, is predominantly studied for neurotrophic signaling. Multiple rodent studies report that intranasal Semax administration was associated with changes in nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) gene expression in regions such as the hippocampus, and with modulation of genes linked to immune and vascular responses in ischemia models. Researchers therefore tend to position Selank around inhibitory neurotransmission and Semax around neurotrophin and cerebrovascular pathways.

Research areas and models each appears in

In the published literature, Selank most commonly appears in anxiety-type behavioral models (elevated plus maze, open field, social interaction tests in rats and mice), withdrawal and stress paradigms, and memory-trace experiments using pharmacological protein-synthesis blockade. Semax appears most often in neuroprotection and cerebral-ischemia models, in pheochromocytoma (PC12) cell trophic-effect studies, in genome-wide brain transcriptional analyses following focal ischemia, and more recently in animal models of Alzheimer's-type amyloid pathology. The two compounds have also been examined side by side: a functional connectomic study investigated how Selank and Semax each relate to resting-state brain connectivity measures, and at least one behavioral study compared the two peptides in the same rat model. These comparisons are descriptions of research observations only.

Which the literature studies for what

Read neutrally, the body of work treats the two peptides as overlapping but differently weighted research tools. Selank is the compound investigators more frequently reach for when the research question concerns anxiety-type behavior, GABAergic gene expression, or stress and withdrawal paradigms. Semax is the compound more often selected when the question concerns neurotrophin (BDNF/NGF) signaling, cerebral ischemia and neuroprotection, or attention- and memory-related endpoints in animals. Several papers note that both are studied as putative cognitive-enhancing research peptides and that their regulatory status and clinical development remain limited. None of this implies suitability for any human application; it simply maps which experimental questions each peptide has historically been used to probe.

How VANTA verifies both

VANTA supplies both Selank and Semax strictly as research-use-only reference materials, not for human or animal consumption. Each compound is characterized for identity and purity using reversed-phase HPLC, with molecular weight confirmed by mass spectrometry. Every lot ships with a per-batch Certificate of Analysis (COA) documenting the analytical results so that laboratory researchers can confirm the material matches the sequence and purity specification before use in any in-vitro or preclinical work. This verification step is about analytical traceability for the lab; it carries no implication of safety or efficacy in any living subject.

Selank vs Semax: A Reference Comparison of Two Studied Regulatory Peptides